Volume 122, Issue 4 , Pages 719-723, October 2008
Increased risk of serious pneumococcal disease in patients with asthma
Background
Individuals with asthma have been reported to be at increased risk of invasive pneumococcal disease (IPD). These findings need to be confirmed in a different population-based study setting.
Objective
We assessed whether serious pneumococcal disease (SPD), defined as an IPD, pneumococcal pneumonia, or both, was associated with asthma status.
Methods
This is a retrospective case-control study using criteria-based methods for ascertaining SPD, as well as asthma. Subjects were residents of Rochester, Minnesota, who had SPD between 1964 and 1983 (the primarily pre–pneumococcal vaccine era) and their age- and sex-matched control subjects using 1:2 matching. Potential cases and control subjects were identified by using the Rochester Epidemiology project database and confirmed by medical record reviews. All cases and control subjects were merged with the database comprising the entire pool of Rochester residents with and without asthma between 1964 and 1983.
Results
A total of 3941 records of potential patients with SPD were reviewed, and we identified 174 cases of SPD (51% male subjects and 94% white subjects). SPD was associated with a history of asthma among all ages (odds ratio, 2.4; 95% CI, 0.9-6.6; P = .09) and among adults (odds ratio, 6.7; 95% CI, 1.6-27.3; P = .01), controlling for high-risk conditions for IPD and smoking exposure. The population-attributable risk percentage was 17% in the adult population.
Conclusion
Adults with asthma might be at increased risk of SPD.
Key words: Asthma, invasive pneumococcal disease, epidemiology, risk, microbial infection, pneumococcal pneumonia, adults, Rochester Epidemiology Project
Abbreviations used: ICD, International Classification of Diseases, IPD, Invasive pneumococcal disease, OR, Odds ratio, PAR%, Population attributable risk percentage, SPD, Serious pneumococcal disease
Supported by a National Institutes of Health grant (R01 AI 56133) from the National Institute of Allergy and Infectious Diseases.
Disclosure of potential conflict of interest: B. P. Yawn is on the advisory board for Schering-Plough; is on the speakers' bureau for AstraZeneca; has received research support from Schering-Plough, AstraZeneca, and Pfizer; and has served as a member of the Minnesota Asthma Coalition and EPR-3 National Heart, Lung, and Blood Institute. P. Wollan has received research support from AstraZeneca and the Agency for Healthcare Research and Quality. R. M. Jacobson has received research support from PSC Corp. The rest of the authors have declared that they have no conflict of interest.
PII: S0091-6749(08)01362-6
doi:10.1016/j.jaci.2008.07.029
© 2008 American Academy of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.
Volume 122, Issue 4 , Pages 719-723, October 2008

